Aurobindo Pharma Limited Q2 Revenue Hits Record Rs 10,263 Crore
Key highlights
- Aurobindo Pharma reported record Q2 FY27 revenue of Rs 10,263 crore, up 24% year on year.
- Operating EBITDA rose 28% to Rs 2,156 crore, lifting the EBITDA margin to 21.0% from 20.3%.
- Consolidated net profit increased 33% year on year to Rs 1,124 crore.
- US revenue grew 25% to Rs 4,555 crore, supported by 10 product launches and 12 final approvals.
powered by IRIS

Aurobindo Pharma reported record Q2 FY27 revenue of Rs 10,263 crore, up 24% year on year, while operating EBITDA rose 28% to Rs 2,156 crore and the margin reached 21%. The September 2026 quarter also delivered a 33% increase in consolidated net profit to Rs 1,124 crore.
Know Aurobindo Pharma inside out
Results, valuation, peers and who's buying, in one view.
How did Aurobindo Pharma perform in Q2 FY27?
Aurobindo Pharma delivered its highest quarterly revenue in the quarter ended September 2026, with consolidated revenue rising from Rs 8,286 crore in Q2 FY26 to Rs 10,263 crore in Q2 FY27. Operating EBITDA increased from Rs 1,678 crore to Rs 2,156 crore, outpacing revenue growth and lifting the EBITDA margin from 20.3% to 21%.
Consolidated net profit increased to Rs 1,124 crore from Rs 848 crore a year earlier. The company also reported sequential momentum, with revenue up 12.2% from the June quarter and profit rising by nearly 9%. The board declared an interim dividend of Rs 7 per share following the quarterly results.
What drove Aurobindo Pharma's quarterly revenue growth?
Aurobindo Pharma's formulations business was the main contributor, generating Rs 9,102 crore in Q2 FY27, up 24% year on year and accounting for about 89% of consolidated revenue. Growth across the US and European formulations businesses, product launches and contributions from acquired operations supported the overall result.
US revenue rose 25% year on year to Rs 4,555 crore. During the quarter, the company launched 10 products in the US, filed seven abbreviated new drug applications, or ANDAs, and received 12 final approvals. Management said the Advair launch occurred in the middle of the quarter, meaning the quarter did not include a full-period contribution from that product.
The Europe formulations business also recorded robust growth despite August being a holiday month in several markets. Europe CEO Venugopalan Muralidharan attributed the performance to market knowledge, supply-chain support, manufacturing headroom and certain opportunistic air-freighted products. He said the business expects growth to continue in upcoming quarters.
Which Q2 FY27 figures were most important for investors?
Aurobindo Pharma's revenue, EBITDA, profit and regional sales data show that both scale and operating profitability improved during the quarter. The widening EBITDA margin is relevant because the company has maintained a FY27 target of a margin above 21%, alongside double-digit revenue growth.
The company reiterated its FY27 guidance for double-digit revenue growth, EBITDA margin above 21%, and absolute EBITDA exceeding Rs 8,000 crore. CFO Santhanam Subramanian clarified that the longer-term EBITDA margin target is 22%, rather than 28%. He identified Lannett integration, better yields and capacity use, the China facility, and biosimilars and biologics as key levers.
Got a follow-up? Ask IRIS
What is the status of Lannett, PenG and new product launches?
Aurobindo Pharma said Lannett is performing close to the overall company EBITDA level, countering an investor concern that the acquired business was diluting profitability. US CEO Swami Iyer said selling, general and administrative cost rationalisation benefits were reflected in Q2 and would continue in phases. However, the Lannett facility remains underutilised, and increasing its utilisation requires regulatory filings and time.
Management also highlighted respiratory, dermal and inhalation opportunities at the Raleigh facility. The site has an approved inhalation product that will be launched when the company is ready, alongside products already filed or under filing and dermal products developed through the India research and development facility.
On the PenG plant, management said prices had increased around 10 to 15 days before the call, with the Indian impact expected after existing inventory is sold over roughly 15 to 20 days. The plant has a capacity of 15,000 tonnes and is currently producing about 10,000 tonnes, compared with Indian demand of about 9,000 tonnes. It is already EBITDA-positive at a low level, while a capacity ramp-up is expected in about six months, subject to regulatory approvals.
How does the quarter affect Aurobindo Pharma's FY27 outlook?
Aurobindo Pharma's Q2 performance places the company within its stated FY27 revenue and margin framework, but the guidance remains management's outlook rather than a reported full-year result. The 21% quarterly EBITDA margin matched the threshold embedded in the company's guidance, while formulations growth and US launches provided the principal operating support during the period.
Management indicated that FY28 could be stronger than FY27, citing a full-year contribution from Lannett, greater activity from China and biosimilars. These initiatives are not yet quantified as FY28 financial guidance. Their eventual contribution will depend on execution, regulatory approvals, product launch timing, capacity utilisation and market conditions in the relevant geographies.
Conclusion
Aurobindo Pharma's Q2 FY27 result showed broad-based growth, with record revenue of Rs 10,263 crore, a 21% EBITDA margin and a 33% increase in net profit. The figures indicate that US and Europe formulations, product approvals and improved operating leverage supported earnings during the September quarter.
Investors will next watch the company's progress toward FY27 guidance of double-digit revenue growth, EBITDA above Rs 8,000 crore and a margin above 21%. Updates on Lannett utilisation, the full-quarter benefit from Advair, PenG capacity ramp-up, the China facility and biosimilar development will be important operating markers.


